PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision
Bioinformatics · 2026
DOI: 10.1093/bioinformatics/btag263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformatics, 2026. Verfasst von Jaemin Jeon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Antigens, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea National Institute of Health, National Research Foundation of Korea, National Research Foundation of Korea Basic Science Research Programs.
Abstract (Originalsprache)
Motivation The identification of protective antigens is fundamentally constrained by sparse annotations and pervasive label uncertainty in reverse vaccinology. Protective antigen–antibody interactions are mediated by a limited subset of surface-accessible residues that form spatially coherent epitopes. This motivates modeling antigenicity at the residue level, where 3D structure provides critical context for functional immune recognition. Moreover, antigen datasets are inherently positive unlabeled: unannotated proteins may contain hidden positives, making reliable negatives difficult to obtain. Results We present PU-GRAIL, a graph neural network framework that integrates protein language model embeddings with predicted 3D structures under positive-unlabeled learning. Trained and evaluated on three benchmark datasets, PU-GRAIL achieves competitive performance compared with existing methods. Importantly, the model’s attention mechanism enables residue-level interpretation, identifying putative epitope regions that correspond to experimentally validated antibody-binding sites. Beyond standard benchmarks, we demonstrate practical utility through (i) severity-associated antigenicity patterns in SARS-CoV-2 patient cohorts, and (ii) proteome-wide vaccine candidate prioritization across 11 bacterial species. Availability and implementation The PU-GRAIL software is available at https://github.com/jaeminjj/PU-GRAIL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Medicine, Seoul National University, Seoul 03080, Republic of Korea.
- School of Computer Science and Engineering, Kyungpook National University, Daegu 41566, Republic of Korea.
- Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
- Center for Data Science, Healthcare AI Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
- Department of Biomedical Science, College of Medicine, Seoul National University, Seoul 08826, Republic of Korea.
ORCID-Profile: Jaemin Jeon, Inuk Jung, Kwangsoo Kim, Jinki Yeom
Förderung
- Korea National Institute of Health
- National Research Foundation of Korea
- National Research Foundation of Korea Basic Science Research Programs
- Korea Health Technology R&D
- Korea Health Industry Development Institute
Zitieren
APA
Jeon, J., Jung, S., Jung, I., Kim, K., & Yeom, J. (2026). PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision. Bioinformatics. https://doi.org/10.1093/bioinformatics/btag263
Vancouver
Jeon J, Jung S, Jung I, Kim K, Yeom J. PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision. Bioinformatics. 2026. doi:10.1093/bioinformatics/btag263
BibTeX
@article{Jeon2026,
author = {Jeon, Jaemin and Jung, Sangwook and Jung, Inuk and Kim, Kwangsoo and Yeom, Jinki},
title = {PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision},
journal = {Bioinformatics},
year = {2026},
doi = {10.1093/bioinformatics/btag263}
}
EUVIMED